Most chemically induced tumors of mice express unique antigens that can be recognized by cytotoxic T lymphocytes (CTL) and thereby mediate tumor rejection. The number of different antigens expressed by a single tumor and their interplay during immunization and rejection are largely unexplored. We used CTL clones specific to individual tumor antigens to examine the number and distribution of CTL antigens expressed by cell lines derived from 3-methylcholanthrene-induced sarcomas of (C57BL/6J • SPRET/Ei)F1 mice. Each tumor cell line expressed one or more antigens that were unique, that is, not detected on cell lines from independent sarcomas. Immunoselection against an immunodominant antigen produced both major histocompatibility complex class I antigen and unique tumor antigen loss variants. Immunization of mice with antigen-negative immunoselected variants resulted in CTL that recognized additional antigens that were also expressed by the progenitor tumor. Some CTL recognized additional unique tumor antigen(s); other CTL recognized a shared antigen expressed not only by the immunizing cell line, but also by independent sarcoma cell lines and untransformed myoblastoid cell lines. CTL that recognized the shared antigen were also recovered from mice immunized in vivo with an untransformed myoblastoid cell line. These findings support a model of immunodominance among chemically induced tumor antigens in which shared antigens are masked by unique immunodominant antigens.
C
hemically induced, transplantable tumors of mice have been used extensively to investigate immunologically mediated tumor rejection (1) , and understanding the cellular mechanisms and molecular antigens responsible for tumor rejection in such mouse models may enable the development of more effective immunotherapies. Historically, studies have used in vivo tumor rejection assays to indirectly investigate antigens expressed by 3-methylcholanthrene (MCA)l-induced tumors. These studies demonstrated that immunization with a chemically induced tumor usually protects against in vivo challenge by the same tumor, but only rarely or sporadically protects against challenge by independent syngeneic tumors (2) (3) (4) . These observations led to the suggestion that the antigens responsible for mediating antitumor immunity to MCA-induced tumors are unique to individual tumors.
More recently, CD8 + CTL have been shown to be necessary for immunity to transplantable sarcomas (5, 6) , and 1Abbreviations used in this paper: CML, cell-mediated lympholysis; MCA, 3-methylcholanthrene; MLTC, mixed lymphocyte tumor culture. the antigens recognized by tumor-specific CTL have come under investigation. Short-term CTL lines from immunized mice have been used to demonstrate that the CTL antigens of MCA-induced sarcomas consist of MHC class I-bound peptides on the cell surface (7) . Each peptide antigen is expressed only by a single sarcoma, correlating with the pattern of in vivo protection. The unique CTL antigens expressed by MCA-induced mouse tumors contrast with the CTL antigens of human melanomas, which are lineage-specific (8, 9) or "activation" (10) antigens expressed by multiple tumors.
The contribution of single antigens to tumor rejection has been investigated in mouse models using in vitro immunoselection to generate CTL-resistant tumor variants that lack expression of the selected antigen. For some highly immunogenic tumors, including spontaneously regressing, UV-induced sarcomas and SV-40 large T antigen-induced sarcomas, multiple epitopes independently mediate rejection (11) (12) (13) (14) . For other UV-induced and some chemically induced tumors, selected loss of an individual antigen produces variants that display a more malignant phenotype than their antigen-expressing progenitor tumors (15) (16) (17) , indicating that the selected antigen is the principal target of tumor re-jection. These studies emphasize the need to assess the spectrum of antigens that are available as targets, and immunoselection provides a powerful tool for exposing secondary epitopes to evaluation.
The use of monoclonal CTL to study antigenic diversity of MCA-induced tumors has been limited. In this report, we use CTL lines and clones to investigate the antigens expressed by cell lines derived from MCA-induced sarcomas of highly heterozygous, (C57BL/6J • SPRET/Ei)F1, termed (B6 • SPE)F/ mice. The antigenic complexity of one tumor cell line was investigated by selecting CTL-resistant variants in vitro and characterizing the immune response to the variants. CTL with new specificities were derived, identifying previously undetected antigens. Some variant-reactive CTL lines defined one or more uniquely expressed antigen(s); other CTL lines defined a shared antigen whose expression could not be inferred from the CTL response against primary cell lines.
Materials and Methods
Tumor Cell Lines. The tumors and their derivative cell lines exanfined in this study have been previously described in detail (18) . Briefly, cell lines were derived from MCA-induced sarcomas generated in male and female mice from an F 1 cross between C57BL/6J (B6) and SPRET/Ei (SPE). All tumor lines were diagnosed histologically as poorly differentiated sarcomas or rhabdomyosarcomas that grew progressively and could be transplanted into syngeneic hosts. Cell lines derived from tumors were grown in 100-mm tissue culture-treated petri plates (Coming Glass Works, Coming, NY) in DMEM-based Vc medium (18) supplemented with 5% FCS (Hyclone Laboratories, Inc., Logan, UT). Cell lines were passaged weekly by preparation of a single-cell suspension using trypsin-EDTA (Sigma Chemical Co., St. Louis, MO) and vigorous pipetting and reseeding fresh plates. For imnmnization and T cell-mediated lympholysis (CML) assays, cells were harvested from petri plates and washed twice in PBS before use. The male-derived tumor cell lines used in this study were bs2 and its clonal derivative, bs2.1; bs4 and its clone, bs4.1; and bs15 and its clone, bs15.1; and the female-derived tumor cell lines were bs9 and its clone, bsg.1. The NK-sensitive Yac-I cell line was passaged weekly in Vc5 medium.
U, tran.fomwd Myoblastoid Cell Lira's. Untransformed myoblasts were derived from (B6 X SPE)F 1 neonates. Muscle tissue was carefully dissected from skin, bone, and fat, minced into fine pieces, and rocked for 1 h at 37~ in 10 ml of HBSS (GIBCO BILL, Gaithersburg, MD) containing 1 mg/ml collagenase and 2.5 U/ml hyaluronidase (Sigma). Large pieces of tissue were allowed to settle out, then suspended cells were washed twice in PBS (GIBCO BRL) and plated in Vcl0 medium in a 100-mm tissue culture-treated cell culture dish (Coming). Myoblastoid cells were passed weekly into fresh Vcl0 (same formulation as Vc5, except with 10% FCS) at a 1-10 dilution.
Mouse lmmlmizations.
(B6 X SPE)F 1 mice (same sex as immunizing tumor) were inmmnized by intraperitoneal injection of 3-5 • 10 ~' irradiated (1,000 Gy) tumor cells admixed with 150 ~g heat-killed Corynebacterium pawum (19; culture kindly provided by Dr. C. Cummins, Virginia Polytechnical Institute and State University, Blacksburg, VA). Immunized mice were boosted at weekly intervals two or three times with 3 • 10 ~' irradiated tumor cells without C. parvum. 10 d to 2 wk after the final boost, animals were euthanized by carbon dioxide asphyxiation, spleens were removed, and mononuclear splenocyte preparations were obtained. Mice for these experiments were bred and housed at The Jackson Laboratory Research Animal Facility following protocols approved by the institutional Animal Care and Use Committee and conforming to the American Association for Accreditation of Laboratory Animal Care (AAALAC) standards.
Mixed Lymphocyte~Tumor Cultures (MLTC) and CTL Lines. Primary MLTC were generated by in vitro culture of 2 • 107 mononuclear splenocytes, 2 • 10 a irradiated (l,500 Gy) tumor cells, 6 ml Vcl0 media, and 25 U/ml IL-2 (a generous gift of M. Widmer, Immunex Corp., Seattle, WA). After 3 d ofm vitro culture, MLTC were expanded 1:3 into Vcl0 with 25 U/ml IL-2. MLTC were passaged weekly thereafter in 16-ram tissue culture wells (Costar Corp., Cambridge, MA) by restimulation of 1-3 • 1115 MLTC cells, 5 • 10 ~ irradiated (200 Gy) syngeneic splenocytes, 1-3 • l0 s irradiated (1,000 Gy) tumor cells, and 25 U/ml IL-2 in Vc medium supplemented with 5-10% fetal bovine serum. Some MLTC were supplemented with 1:20 volume anti-CD4 ascites fluid (clone GK1.5) during the third and fourth passages to block antigen-specific CD4 + cell proliferation. After five or six passages in vitro, MLTC usually exhibited consistent growth characteristics from week to week, and were considered to be stable CTL lines. CTL clones were derived from established CTL lines by micromanipulation of single cells as previously described (20) . For restimulation before CML assays, MLTC and CTL were passaged as described above, but with 30-40 U/ml IL-2; and cell supernatants were replaced 24 h before assay with fresh Vc5 supplemented with 5 U/ml IL-2.
The ( CML Assay. 4-6-h CML assays were performed as previously described (23) . 51Cr released into the supernatant was determined, and specific lysis was calculated using the following ratio:
specific lysis = (experimental -spontaneous) / (maximum --st~ontam'ol~s )
Data are reported as the mean of three wells. SDs (generally <5%) are omitted for clarity of presentation. The ability of vari-ous antibodies to inhibit target lysis was determined by the addition of 1/20 vol antibody ascites to microplate wells. In some experiments, tumor target cells were grown in 5 U/ml IFN-y (a generous gift from Dr. van der Meide, Biomedical Primate P,,esearch Center, Rijswijk, The Netherlands) for 48 h before assay to augment surface expression of MHC class I molecules. T cell lymphoblast target cells were cultured from splenocytes in Vc5 supplemented with 25U/ml IL-2 and 2 I~g/ml Con A (Sigma). These cells were used as CML targets 2-5 d later.
Results

(B6 • SPE)F I Tumors Express Unique Tumor Antigens.
Tumor cells lines were used to immunize (B6 • SPE)F1 mice, and CTL lines were derived from inmaunized splenocytes by in vitro restimulation. Fig. 1 Four additional mice were immunized, and their splenocytes were restimulated in vitro using tumor cell line bs15.1. All four MLTC specifically lysed the cognate tumor, bs15.1, but failed to lyse the tumor antigen-specific variant, 15A1 (not shown), indicating that the CTL populations in these additional MLTCs recognize the same unique tumor antigen as CTL BXS/15.4. The H2Kb-restricted bs15.1 antigen recognized by all these CTLs is therefore immunodominant, in that it is highly effective at eliciting CTL under the culture conditions used.
Three additional MLTC were established from splenocytes of mice immunized with tumor cell line 15A1 and restimulated with 15A1 cells (Fig. 4) . MLTC 2/A and 3/A demonstrated potent specific lysis of bsl5.1 cells and variants 15V.1 and 15A1, but not of tumor cell line bs4.1 or untransformed myoblasts. This pattern of reactivity is identical to that exhibited by the CTL line BxS/V, and indicates recognition of a secondary tumor-specific antigen(s). MLTC 1/A demonstrated relatively high lysis of Yac-1 targets, indicating NK-like or LAK-like nonspecific cytotoxicity, but litde additional sarcoma-specific lyric activity. MLTC 2/A and 3/A also initially demonstrated low levels oflysis of sarcoma bs4.1 and untransformed myoblastoid lines (replicate experiments, not shown). This lytic activity could indicate a minor population of CTL that recognized a shared antigen with the same specificity as the BxS/A line.
Immunization with Untransformed Myoblasts Primes against a Shared Tumor Antigen. Four mice were immunized with untransformed myoblasts. Splenocytes from these mice were split, and one half was restimulated using untransformed myoblasts while the other half was restimulated using tumor cell line 15A1. All MLTC derived by restimulating in vitro using myoblasts failed to lyse any target tested. However, three of the four MLTC from myoblast-immunized splenocytes that were restimulated with tumor cell line 15A1 demonstrated target cell lysis. All three MLTC exhibited lysis of bs 15.1, bs4.1, and untransformed myoblasts, but not of Yac-1 cells or splenic T cell blasts. One example 445 Dudley and Roopenian of a pair of MLTCs derived from splenocytes of a single mouse, but restimulated using two different antigen sources, is shown in Fig. 5 . The antigen specificity exhibited by the MLTC from myoblast-immunized, tumor-restimulated MLTC recapitulates the target specificity exhibited by CTL BxS/A.
Discussion
Despite the widespread use of MCA tumors for investigating immunological tumor rejection (1, 17) immunized and restimulated with syngeneic MCA-induced sarcoma cell lines exhibit specific lysis of their cognate (immunizing) tumor cell lines. Lysis of independent tumor cell lines was not observed, indicating that the primary CTL antigens expressed by MCA-induced sarcomas are uniquely expressed by individual tumors. These results recapitulate and extend the extensively replicated observation that chemically induced and W-induced sarcomas are inununogenic, but fail to elicit cross-protective immunity (7, 24) . The genetic mechanisms by which tumor cells escape CTL lysis can be studied by applying an in vitro CTL immunoselection approach. We observed that selective pressure on the highly heterozygous tumor cell line bs15.1 resulted in both MHC antigen variants and unique tumor antigen variants. It is interesting that these variant phenotypes reflect mutational alterations also observed in human and mouse tumors in vivo (25) (26) (27) , suggesting that CTL selective pressure can shape tumor progression in patients. Because (B6 X SPE)F 1 tumor cell lines comprise abundant polymorphism between B6 and SPE alleles throughout the genome, they should expedite genetic analysis of mutations accompanying antigen loss after immunoselection and provide a powerful tool for understanding genetic mechanisms of tumor progression.
To investigate the antigenic complexity of tumor cell line bs15.1, variants lacking expression of the immunodominant antigen were exploited for detecting additional CTL antigens. Two qualitatively different, secondary antigens of tumor bs15.1 elicit CTL. A secondary tumor-specific antigen is recognized by CTL BxS/V. Expression of multiple tumor-specific antigens by a single tumor has been previously reported, including UV-induced sarcomas with highly immunogenic "regressor" phenotypes (11, 17). Expression of multiple tumor-specific antigens by MCA-induced tumors is therefore not unexpected, although it has not been extensively reported. More surprising is the observation that a shared antigen recognized by CTL BxS/A.11 is expressed by independent MCA-induced sarcomas as well as untransformed myoblastoid cell lines. Shared antigens were unexpected under these experimental circumstances because no cross-reactive lytic activity was generated in bulk MLTCs against the progenitor bs15.1 cell line, and shared antigens of UV-induced and MCA-induced tumors are not routinely observed using in vitro approaches or in vivo cross-protection assays.
The three CTL antigens expressed by tumor cell line bs15.1 exhibit a gradation ofimmunodonfinance under the experimental conditions used to generate MLTC. The primary tumor-specific antigen monopolized the CTL response when it was expressed by the immunizing/restimulating tumor. Most MLTC generated by using primary antigen-loss variants 15A1 and 15V.1 recognized the tumor-specific secondary antigen, although one MLTC recognized the shared antigen. Finally, although the shared antigen appears to be the weakest of the three CTLdefined antigens, under appropriate conditions, the shared antigen-specific CTL activity was reproducibly generated. The failure to observe persistent lytic activity aimed at more than a single antigen suggests that these activities may be mutually exclusive. Thus, these results support the hypothesis that immunodominant, tumor-specific antigens of MCA-induced tumors not only provoke a strong, tumorspecific CTL response, but they may also suppress or mask responses against weaker antigens, including both secondary tumor-specific antigens and shared antigens.
The coexpression of immunodominant tumor-specific antigens and secondary, shared antigens may explain sporadic reports of in vivo cross-protection in immunized animals. While most studies investigating in vivo rejection indicate that cross-protection between MCA sarcomas is rare (3, 4, 28) , sporadic cases of cross-protection have been reported: Basombrio (4) demonstrated replicable cross-protection with one combination out of 14 MCA-induced tumors, and Prehn and Main (2) showed significant crossprotection in two of the four tumor combinations they tested. This rare in vivo cross-protection may reflect sporadic priming against a shared sarcoma antigen in the context of frequent priming against unique antigens. Further studies are needed to characterize the nature of the shared antigen detected on (B6 • SPE)F~ sarcomas and to evaluate the efficacy of shared-antigen specific CTL for tumor rejection in vivo. The use of untransformed myoblastoid cell lines to prime a CTL response against shared antigens offers a new tool to dissect the potential role of shared antigens in tumor rejection.
